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Abstract There is tremendous scientific interest in the
analysis of gene expression data in clinical settings, such
as oncology. In this paper, we describe the importance of
adjusting for confounders and other prognostic factors in
order to select for differentially expressed genes for
follow-up validation studies. We develop two approaches
to the analysis of microarray data in non-randomized
clinical settings. The first is an extension of the current
significance analysis of microarray procedures, where
other covariates are taken into account. The second is a
novel covariate-adjusted regression modelling based on
the receiver operating characteristic (ROC) curve for the
analysis of gene expression data. The ideas are illustrated
using data from a prostate cancer molecular profiling
study.
Keywords Differential expression . Gene expression .
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Introduction
With the advent of high-throughput gene assay technol-
ogies, scientists are now able to measure genome-wide
mRNA expression levels in a variety of settings. An
example of this are DNA microarrays (Schena 2000). One
of the major tasks in studies involving these technologies
is to find genes that are differentially expressed between
two experimental conditions. The simplest example is to
find genes that are up-regulated or down-regulated in
cancerous tissue relative to healthy tissue. Typically in
these experiments, the number of genes, represented as
spots on the biochip, is much larger than the number of
independent samples in the study. Consequently, assessing
differential expression in this setting leads to performing
several thousand hypothesis tests, which leads to the
problem of multiple comparisons.
Our work is motivated by a gene expression profiling
study in prostate cancer. The goal is to determine if gene
expression profiles can be used to classify various types of
prostate cancer. In our studies (Dhanasekaran et al. 2001;
Varambally et al. 2002), we have profiled tissue samples
from various stages of prostate cancer (normal adjacent
prostate, benign prostatic hyperplasia, localized prostate
cancer, advanced metastatic prostate cancer) using 10K
cDNA microarrays. This gene expression database is
linked to a clinical and tissue microarray database and
housed in the Chinnaiyan lab at the University of
Michigan. Consequently, in addition to the gene expres-
sion profiles for a sample, the investigators have access to
several other clinical parameters, such as Gleason score,
survival time and status, and time to PSA recurrence.
Throughout the profiling studies, investigators have made
the following hypotheses:
1. There exists a set of genes that distinguish lethal
prostate cancer from non-lethal prostate cancer.
2. Distinct sets of genes and proteins dictate progression
from precursor lesion, to localized disease, and finally
to metastatic disease.
The importance of the first hypothesis is for prognostic
purposes. Distinguishing indolent prostate cancer from
aggressive disease will impact treatment decisions. The
hypotheses address the potential of microarray technolo-
gies to develop a molecular classification for cancer that
has a higher resolution than traditional histopathological
staging systems. The second hypothesis is more biological
in nature and is focused upon learning about which genes
are involved in cancer progression. The cDNA micro-
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arrays also serve a screening role in that a subset of the
genes that show significant differential expression will be
assayed on a proteomic level using tissue microarrays
(Kononen et al. 1998). Because of the fact that our gene
expression database is linked to the tissue microarray
database, it is relatively easy to validate the gene
expression results at the protein level using tissue
microarrays.
The analyses in our previous studies have focused on
comparing gene expression profiles from two conditions.
In the setting of a single study, differential expression for
microarray data is a well-studied problem: see, for
example, the work of Efron et al. (2001), Dudoit et al.
(2002), Lonnestedt and Speed (2002) and Ibrahim et al.
(2002). Recently, several authors have advocated use of
the false discovery rate (FDR; Benjamini and Hochberg
1995) for the problem of testing multiple hypotheses
simultaneously (Efron et al. 2001; Storey 2002). This
quantity is different from the familywise error rate
(FWER) that is typically controlled in multiple testing
problems (Westfall and Young 1993).
While much of this multiple testing literature is geared
towards controlling the rate of false positives using a
proper calibration, in practice the outputs of these analyses
are used as a screening procedure for investigators in order
to find candidate biomarkers to validate on a protein level.
A related argument was also given by Pepe et al. (2003),
who suggested a method of ranking genes based on
measures of discrimination using the receiver operating
characteristic (ROC) curve.
A feature common in cancer studies is the availability of
additional clinical information, such as a staging variable,
survival time, baseline covariates and treatment. In
virtually all of the scientific literature dealing with
microarrays, the major comparison done is between
cancerous and non-cancerous tissue. However, if the
biomarker does not offer an improvement in terms of
discriminative ability relative to the usual staging systems,
then it does not serve well as a diagnostic biomarker.
Potential biomarkers will be of benefit if they can provide
this additional information.
More generally, the samples used for microarray
profiling are typically collected in the context of an
observational study. Unlike a clinical trial, where subjects
are randomized to a treatment group, no such randomiza-
tion assignment occurs in observational studies. In most
published analyses of microarray data, the assessment of
differential expression is not adjusted for potential
confounders such as age and race. While this is commonly
done in epidemiological studies, it has not been utilized
very much in the analysis of microarray data. If the
potential confounders are not adjusted for, then differences
in gene expression between cancerous and non-cancerous
samples will be confounded with differences between
tumor sample characteristics.
In this paper, we discuss the importance of covariate
adjustment in the analysis of microarray data from clinical
experiments and develop some new analytical methodol-
ogies for selecting genes. The structure of this paper is as
follows. In “Data description,” we give a brief background
on the data used to illustrate the ideas in the paper. We
describe the concept of FDR and develop its link to
quantities from the diagnostic testing literature in “Mul-
tiple testing procedures.” In “Statistical methods,” we
present two methods for gene selection. The first is a
covariate-adjusted FDR estimation procedure. The second
is estimation of a covariate-adjusted ROC curve. The
methods are applied to data from the prostate cancer study
in “Results“. Finally, we conclude with some brief
discussion in “Discussion.”
Data description
The dataset we will be using to illustrate the ideas in the
paper is from an ongoing molecular profiling study in
prostate cancer. The benign and malignant prostate tissues
were analyzed using a 9,984-element (10K) human cDNA
microarray. The glass slide cDNA microarrays developed
for this study include approximately 5,000 known, named
genes from the research genetics human cDNA clone set,
4,400 ESTs, and 500 control elements (which include
Table 1 Primary tumor clinical
definitions (taken from Ameri-
can Joint Committee on Cancer
2002, p. 340)
Value Definition
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Clinically unapparent tumor neither palpable nor visible by imaging
T1a Tumor incidental histologic finding in 5% or less of tissue resected
T1b Tumor incidental histologic finding in 5% or more of tissue resected
T1c Tumor identified by needle biopsy
T2 Tumor confined within prostate
T2a Tumor involves one-half of one lobe or less
T2b Tumor involves more than one-half of one lobe but not both lobes
T2c Tumor involves both lobes
T3 Tumor extends through the prostate capsule
T3a Tumor invades seminal vesicles
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles: bladder neck, external
sphincter rectum, levator muscles, and/or pelvic wall
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genomic human, rat, and yeast DNAs, and yeast genes).
As is common with other spotted cDNA microarrays, the
test and reference samples were labeled with Cy5 and Cy3
dyes and competitively hybridized to the microarray.
While there are 9,984 genes on the original array, we did
some preprocessing to reduce the number of genes
considered. We removed genes that were missing on
more than 10% of the samples as well as those having
variance across all samples less than 0.05. This left a total
of G =4,880 genes profiled on n =78 samples.
The data consist of (Ygi, Zi, Si, Ai), where Ygi is the gene
expression measurement on the gth gene (g =1,⋯, 4,880)
for the ith subject, Zi denotes presence or absence of tumor
(1 denotes tumor present, 0 denotes tumor absent), Si is the
clinical staging of the tumor from which the sample came
and Ai is the age of the patient that provided the ith sample
(i =1,⋯, 78). Age is included in the analysis because it is a
potential confounder that we will want to adjust for in the
analysis. We now describe the stage covariate further.
All tumor specimens have a mixture of cancerous and
normal tissue. They are stored in paraffin-embedded
blocks, a slice of which is used for the microarray
experiments. The variable S refers to the stage for the
specimen, but the given slice used for the microarray
experiment may or may not have tumor. The variable Z
refers to the slice of tissue used. Because Z and S were not
perfectly correlated and S has been shown to a prognostic
factor for biochemical recurrence, we decided to include it
in the analysis.
The standard prostate cancer staging system is provided
by the American Joint Committee on Cancer (2002, pp.
337–345). It consists of scoring the primary tumor (T), the
regional lymph nodes (N) and distant metastases (M). The
tumor falls into one of four stages based on the
combination of T, N and M scores. In Table 1, we provide
the definitions of the values of this variable.
Going back to the hypotheses formulated by the
investigators, it is reasonable that biomarkers of interest
should be those that have predictive power above and
beyond the stage variable S. In “Statistical methods,” we
describe methods for adjusting for covariates in the
analysis. We first describe some multiple testing methods
and their links to classification ideas.
Multiple testing procedures
In most analyses of microarray data in cancer studies, the
major inferential tool for assessing differential expression
is using multiple testing procedures. Examples include the
methods of Efron et al. (2001) and Dudoit et al. (2002).
Background
Suppose we are interested in testing a set of m hypotheses.
Of these m hypotheses, suppose that for m0 of them, the
null is true. To guard against making too many type I
errors, the FWER has typically been controlled. A review
of methods for controlling this quantity can be found in
Shaffer (1995). To better understand the FWER and FDR,
we consider the 2×2 contingency table given in Table 2.
Using the definitions from Table 2, the FWER is
defined to be P (V ≥1), which is the probability that the
number of false positives is greater than 1. The definition
of FDR as put forward by Benjamini and Hochberg (1995)
is




P Q > 0ð Þ:
The conditioning on the event [Q >0] is needed because
the fraction V/Q is not well-defined when Q =0. Storey
(2002) points out the problems with controlling this
quantity and suggests use of the positive FDR (pFDR),
defined as





Conditional on rejecting at least one hypothesis, the pFDR
is defined to be the fraction of rejected hypotheses that are
in truth null hypotheses. In words, the pFDR is the rate at
which discoveries are false. This quantity is analogous to
type I error rates in single hypothesis testing problems.
The FDR and pFDR refer to one type of mistake that
can be made during the hypothesis testing process. The
other class of mistake that can be made is that while the
alternative hypothesis is true, in practice we fail to reject
the null hypothesis. This is similar to making a type II
error. Thus, we define the false non-discovery rate (FNR)
and positive FNR (pFNR) to be




P W > 0ð Þ
and





Conditional on failing to reject at least one hypothesis,
the pFNR is the fraction of accepted hypotheses that are in
truth alternative hypotheses. As with pFDR, we condition
on [W >0] because T/W is not well-defined when W =0.
Heuristically, pFNR can be thought of as the rate at which
discoveries are missed.
Suppose we have independent test statistics T1,⋯, Tm,
for testing m hypotheses. Define corresponding indicator
Table 2 Outcomes of m tests of
hypotheses
Accept Reject Total






variables H1,⋯, Hm where Hi =0 if the null hypothesis is
true and Hi =1 if the alternative hypothesis is true. We
assume that H1,⋯, Hm are a random sample from a
Bernoulli distribution where for i =1,⋯, m, P Hi ¼ 0ð Þ ¼
0 . We assume that TijHi ¼ 0  f0 and TijHi ¼ 1  f1
for densities f0 and f1 (i =1,⋯, m). Suppose we use the
same rejection region R for testing each of the m
hypotheses. By a theorem from Storey (2002), we have
that
pFDR Rð Þ ¼ P H ¼ 0jT 2 Rð Þ
¼ 0P T2RjH¼0ð ÞP T2Rð Þ :
This development has assumed that expression measure-
ments were independent across genes. This is not very
realistic, as we expect dependence between genes to occur
because of involvement in common pathways. Storey
(2002) mentions that FDR estimation procedures are not
very sensitive to dependence among genes.
For a fixed R, we see pFDR and pFNR as being related
to well-known quantities in diagnostic testing. If we define
the events T ¼ 1½   T 2 R½  and T ¼ 0½   T 2 Rc½  ,
then the positive and negative predictive values of T are
given by PPV ¼ P H ¼ 1jT ¼ 1ð Þ and NPV ¼ P
H ¼ 0jT ¼ 0ð Þ . Note that we have suppressed depen-
dence of PPV and NPV on R. Then simple algebra yields
pFDR Rð Þ ¼ 1 PPV and pFNR Rð Þ ¼ 1 NPV . Thus,
the procedures of Storey (2002) for estimating pFDR(R)
can be thought of as estimating a type of positive
predictive value. This link has also been observed by
Storey (2003). However, we do not know ahead of time
the “diseased” and “undiseased” populations, which are
the set of true alternative and null alternative hypotheses.
Note that π0 in these formulae is analogous to prevalence
in PPV and NPV calculations. We have to estimate this
quantity here as well. There are several approaches one
can consider. In the work of Efron et al. (2001) and Storey
(2001), π0 is estimated via permutation methods. A natural
Bayesian method is to place a prior on π0; this corresponds
to the biologist’s knowledge as to the percentage of
differentially expressed genes in the experiment. The prior
for π0 will depend very much on the setting in which the
investigator is applying microarrays. For the cancer data
we are considering here, the investigators expect many
genes to be differentially expressed.
While the pFDR and pFNR are useful quantities for
estimation in high-throughput studies, their values depend
on the estimated proportion of non-differentially expressed
genes, similar to the manner in which estimates of PPV
and NPV depend on estimated prevalence.
Another useful quantity for discriminating between
diseased and healthy populations is the ROC curve. An
advantage of the ROC curve is that its estimation does not
require having to estimate the proportion of non-
differentially expressed genes. Suppose Yg
D represents
the gene expression measurement for the gth gene for a
typical cancer specimen, i.e., D =1, and Yg
D̄ is the
corresponding measurement for a randomly chosen benign
specimen, i.e., D =0. Assume that higher values of Yg
correspond to having the disease. One relevant quantity is
the false positive rate based on a cutoff c, defined to be
FP cð Þ ¼ P Yg > cjD ¼ 0
 
. Similarly, the true positive
rate is TP cð Þ ¼ P Yg > cjD ¼ 1
 
. The true and false
positive rates can be summarized by the ROC curve,
which is a graphical presentation of
TPðcÞ;FPðcÞ : 1 < c < 1f g . The ROC curve
shows the tradeoff between increasing true positive and
false positive rates. Tests that have {TP(c), FP(c)} values
close to (0,1) indicate perfect discriminators, while those
with {TP(c), FP(c)} values close to the 45° line in the
(0,1)×(0,1) plane are tests that are unable to discriminate
between the diseased and healthy populations. Examples
of ideal and non-informative ROC curves are given in
Fig. 1.
In the next section, we develop two procedures for
assessing the explanatory power of biomarkers over and
above existing clinical information. The first involves a
generalization of FDR estimation procedures, while the
second deals with use of the ROC curve, adjusting for
covariates.
Statistical methods
Linear model-based false discovery rate
We now present a method for assessing differential
expression based on direct estimation of the FDR where
potential confounders are adjusted. We fit the model
E Yig
  ¼ 0g þ 1gZI þ 2gAI þ 3gSI (1)
Our scientific focus in Eq. 1 is making inference about
β1g, which represents the difference in gene expression
between cancerous and healthy tissue for the gth gene,
adjusting for age and staging of the specimen. It is obvious
Fig. 1 Receiver operating characteristic (ROC) curves for ideal (a)
and non-informative (b) tests
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that fitting Eq. 1 is equivalent to fitting univariate linear
models on a gene-by-gene basis. The model in Eq. 1 can
be fit using ordinary least squares (OLS), yielding a set of
statistics T11,⋯, T1G, where T1g is the least squares
estimator of β1g divided by its estimated standard error. If
we use a normal distribution with mean 0 and variance 1
as the null distribution for testing H0g : 1g ¼ 0 , then we
have Gp-values p1,⋯, pG. We then can apply Algorithm 1
of Storey (2002) to estimate the gene-specific FDR; it is
summarized in the Appendix.
Note that because we are working with the t-statistics,
this is a conditional method, where the conditioning is on
the t-statistic values themselves. The unconditional meth-
od involves permuting the Z labels and refitting Eq. 1 to
the permuted dataset. There are two potential problems
with the use of the unconditional approach here. First, for
large sample sizes, permutation methods on the full dataset
may be quite computationally intensive. Second, the
validity of permutation tests relies on the fact that under
the null hypothesis of no differential expression, the
distribution of permuted group assignments is exchange-
able. Because we are explicitly incorporating the observa-
tional nature of the study through covariate adjustment in
Eq. 1, it is not clear whether the distribution will be
exchangeable. Thus the validity of permutation techniques
for the gene expression data is questionable.
Receiver operating characteristic curve estimation
Pepe et al. (2003) discussed the use of ROC methods for
finding candidate genes in the two-sample problem. In this
section, we extend their method to allow for adjustment
with covariates. Pepe (2000) showed that the ROC curve
at a value t (t∈[0,1]) has an interpretation of P
YDg > Y
D




. Based on this fact, we can
formulate the following approach for ranking genes based
on the ROC curve.
1. Estimate the residuals from fitting Eq. 1 for each gene;
this yields the estimates êig , I= 1,⋯, 78, g =1,⋯,
4,880. This will determine the appropriate direction to
consider for calculating the ROC curve.
2. Determine if the sample mean of êig for the cancer
samples are higher or less than êig for the healthy
samples.
3. Estimate the ROC curve based on the residuals.
We work by estimating the residuals based on point 2
and calculating univariate ROC curves based on them. It
should be mentioned that because of the form of the
model, the mean residuals will not be zero within tumor
type. If we generalized Eq. 1 to allow for interactions
between A and S with tissue type, then the average of
residuals would be zero. Based on estimating the ROC
curves for each gene, we can consider ranking the genes
on several possible quantities. One is the area under the
curve:
Fig. 2 Results from multiple
testing analyses between cancer
and non-cancer samples using





ROC tð Þdt ¼ P YDg > Y Dg
 	
: (2)
A second quantity is the partial area under the curve,
restricted in the range from 0 to t0:
pAUC t0ð Þ ¼
Zt0
0
ROC tð Þdt; (3)
where t0 is some small false positive rate. This is typically
done because the value of the entire ROC curve is
typically not of interest to investigators for the purposes of
selecting genes. Instead, what is of interest is the value of
ROC for small false positive rates, or equivalently, for
small sensitivity values. Another measure that focuses the
ROC curve for small false positive rates is ROC (t0):
ROC t0ð Þ ¼ P YDg  yC 1 t0ð Þ
 	
: (4)
One way in which the ROC values (Eqs. 2–4) provide
complementary information to that given by the p-values
for β1g in Eq. 2 is that ROC-based quantities summarize
the potential discriminative abilities of biomarkers.
Results
We now describe the application of the proposed meth-
odology to the prostate cancer data described in “Data
description.” We first began by performing a simple
analysis using two-sample t-tests (i.e., comparing gene
expression samples with Z =0 and Z =1) and estimating the
gene-specific FDR (Storey 2002); the results are provided
in Fig. 2. Based on this plot, we see that approximately
43.3% of genes are being estimated as non-differentially
expressed between cancerous and healthy samples. Based
on the plot, it also appears that the false positive rate is
fairly low even for moderately large numbers of
significance tests; this information is provided by the
figure in the bottom right corner of Fig. 1.
In the next analysis, we fit Eq. 1 and estimate the gene-
specific FDRs using the methods outlined in “Linear
model-based false discovery rate”; the resulting plot is
given in Fig. 3. We find that a greater percentage of genes
are estimated as non-differentially expressed. We see that
the reduction in number of genes called significant
between the two analyses ranges from about 30% to
50%. This suggests that differences in gene expression
from the previous analysis were partially due to differ-
ences in clinical stage and/or age of the tissue specimen. If
we were to focus our attention on individual gene lists and
rank the genes based on the p-values, we find that there is
some overlap between the two. There is 80% overlap
between the two lists for the top 20 genes. This overlap
drops to 74% for the top 100 genes and 69.5% for the top
1,000 genes.
We next ranked genes based on AUC, pAUC and ROC
(t0), where we took t0 =0.1. The lists of top 20 genes based
Fig. 3 Results from multiple
testing analyses assessing dif-
ferential expression between
cancer and no cancer adjusting
for age and clinical stage of
tumor
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on these scores are given in Tables 3, 4, 5, and 6. If we
compare them to those using q-values, we now find
minimal overlap. In fact, there is only one gene common
to both. The overlap between genes based on the ROC
measures and q-values is about 5% for the top 100 and
18.5% for the top 1,000. This suggests the q-value is not
adequately able to capture the discriminative power of the
biomarker. Using arguments similar to those in Pepe et al.
(2003), what is happening is that the linear model method
is picking up the genes that show the smallest variation,
while the ROC method is picking up the genes with higher
discriminatory power.
Table 3 Top 20 differentially
expressed genes based on ad-
justed q-values. The data were
fit using Eq. 1 so that an
adjustment for age and stage
was made
Unigene ID Gene name
Hs.85155-or-Hs.33905 Zinc finger protein 36, C3H type-like 1-or-ESTs
Hs.83951 Hermansky-Pudlak syndrome 1
Hs.139851 Caveolin 2
Hs.76252 Endothelin receptor type A
Hs.171731 Solute carrier family 14 (urea transporter), member 1 (Kidd blood group)
Hs.342874 Transforming growth factor, beta receptor III (betaglycan, 300 kDa)
Hs.352554 Homo sapiens cDNA FLJ31353 fis, clone MESAN2000264
Hs.343522 ATPase, Ca++ transporting, plasma membrane 4
Hs.4909 Dickkopf homolog 3 (Xenopus laevis)
Hs.6838 RAS homolog gene family, member E
Hs.374441 Human calmodulin-I (CALM1) mRNA, 3′UTR, partial sequence
Hs.124029 Inositol polyphosphate-5-phosphatase, 40 kDa
Hs.93005 Snail homolog 2 (Drosophila)
Hs.301853 RAB34, member RAS oncogene family
Hs.75350 Vinculin
Hs.342874 Transforming growth factor, beta receptor III (betaglycan, 300 kDa)
Hs.272927 Sec23 homolog A (S. cerevisiae)
Hs.104105 Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse)
Hs.100554 ESTs
Hs.79339 Lectin, galactoside-binding, soluble, 3 binding protein
Table 4 Top 20 differentially expressed genes based on AUC
Unigene ID Gene name
Hs.351622 Pyruvate dehydrogenase complex, lipoyl-containing component X; E3-binding protein
Hs.325825 Homo sapiens cDNA FLJ20848 fis, clone ADKA01732
Hs.279798 Placenta-specific 7
Hs.86437 Homo sapiens gastric cancer-related protein GCYS-20 (gcys-20) mRNA, complete cds
Hs.170285 Nucleoporin 214 kDa (CAIN)
Hs.30120 ESTs, weakly similar to NUCL_HUMAN NUCLEOLIN [H. sapiens]
Hs.287820 or
Hs.211579
Fibronectin 1 or melanoma cell adhesion molecule
Hs.165216 ESTs
Hs.301451 ESTs, weakly similar to GNMSLL retrovirus-related reverse transcriptase homolog—mouse retrotransposon [M.
musculus]
Hs.2910 Phosphoribosyl pyrophosphate synthetase 2
Hs.28700 Homo sapiens, clone IMAGE: 3685952, mRNA
Hs.19377 ESTs, highly similar to B30142 pepsin A [H. sapiens]
Hs.43910 CD164 antigen, sialomucin
Hs.99423 or
Hs.145020
ATP-dependent RNA helicase or ESTs, weakly similar to KIAA1205 protein [H. sapiens]
Hs.9663 Programmed cell death 6 interacting protein
Hs.301612 FOS-like antigen 2
Hs.70704 Chromosome 20 open reading frame 129
Hs.143434 Contactin 1
Hs.46849 ESTs
Hs.278385 or Hs.6088 ESTs or a disintegrin and metalloproteinase domain 11
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Table 5 Top 20 differentially
expressed genes based on
pAUC (the AUC was restricted
to false positive rates less than
or equal to 0.1)
Unigene ID Gene name
Hs.351622 Pyruvate dehydrogenase complex, lipoyl-containing component X; E3-binding
protein
Hs.279798 Placenta-specific 7
Hs.86437 Homo sapiens gastric cancer-related protein GCYS-20 (gcys-20) mRNA,
complete cds
Hs.170285 Nucleoporin 214 kDa (CAIN)
Hs.30120 ESTs, weakly similar to NUCL_HUMAN NUCLEOLIN [H. sapiens]
Hs.287820 or
Hs.211579
Fibronectin 1 or melanoma cell adhesion molecule
Hs.325825 Homo sapiens cDNA FLJ20848 fis, clone ADKA01732
Hs.165216 ESTs
Hs.28700 Homo sapiens, clone IMAGE: 3685952, mRNA
Hs.9663 Programmed cell death 6 interacting protein
Hs.19377 ESTs, highly similar to B30142 pepsin A [H. sapiens]
Hs.301451 ESTs, weakly similar to GNMSLL retrovirus-related reverse transcriptase
homolog—mouse retrotransposon [M. musculus]
Hs.99423 or
Hs.145020
ATP-dependent RNA helicase or ESTs, weakly similar to KIAA1205 protein [H.
sapiens]
Hs.2910 Phosphoribosyl pyrophosphate synthetase 2
Hs.143434 Contactin 1
Hs.78065 Complement component 7
Hs.21594 RAS-like, estrogen-regulated, growth-inhibitor
Hs.70704 Chromosome 20 open reading frame 129
Hs.43910 CD164 antigen, sialomucin
Hs.301612 FOS-like antigen 2
Table 6 Top 20 differentially
expressed genes based on ROC
(0.1)
Unigene ID Gene name




Hypothetical protein FLJ22242 or Homo sapiens cDNA FLJ32731 fis, clone
TESTI2001134
Hs.348955 ESTs, weakly similar to A43932 mucin 2 precursor, intestinal [H. sapiens]
Hs.172788 ALEX3 protein




Mitochondrial ribosomal protein S15 or EphB1
Hs.155560 Calnexin
Hs.39982 ESTs
Hs.106728 Homo sapiens, clone IMAGE: 4686377, mRNA
Hs.175955 ESTs, weakly similar to hypothetical protein FLJ11267 [Homo sapiens]
Hs.50966 Carbamoyl-phosphate synthetase 1, mitochondrial
Hs.5822 Homo sapiens cDNA: FLJ22120 fis, clone HEP18874
Hs.39785 ESTs









In this manuscript, we have stressed two ideas in the
analysis of microarray data. The first is adjustment for
variables that might be confounders or that might increase
precision of the estimated difference in gene expression
between samples from different conditions (e.g., cancer
versus non-cancer tissue). This is important because in
most settings the samples are collected in an observational
study, which is subject to various biases. In most analyses
of gene expression data, confounders and precision
variables are not usually taken into account in assessing
differential expression. We have done this through use of
model/Eq. 1. Alternative methods for achieving the
adjustment include matching and stratification.
The second idea emphasized here is the use of ROC
curves for gene selection in microarray experiments. ROC
curves have been utilized heavily in classification
problems. One of the advantages of this method is that it
does not depend on the estimated proportion of non-
differentially expressed genes, while the approaches of
Efron et al. (2001) and Storey (2002) do. The methodol-
ogy we have described here is a generalization of that
given in Pepe et al. (2003).
The analytic approaches described in the paper were
primarily based on Eq. 1. This model can be generalized in
several ways. First, we could include additional covariates
on the right-hand side of Eq. 1, along with interactions
with cancer status. Second, the linear model can be
extended to the class of generalized linear models
(McCullagh and Nelder 1999; Fahrmeir and Tutz 2001)
in a normal fashion in order to accommodate other types
of clinical responses.
For example, an alternative analysis to the one proposed
here would be to fit a logistic regression model where the
dependent variable is presence or absence of cancer, and
the predictors are the gene expression level, age, and stage.
The method can then be applied to the coefficient of Y.
This model should achieve the same end that the authors
seek, namely, to account for the effects of age and stage on
the discovery of biomarkers.
While we have focused on the analysis of gene
expression data, it is also useful to incorporate statistical
considerations in the design of gene expression experi-
ments. It is an area we are currently pursuing.
In a recent paper, Pepe et al. (2001) provide guidelines
as to the development of new biomarkers for the early
detection of cancer. They argue eloquently for the use of
the ROC curve. In addition, they make the case that the
potential exists for confounders to obscure the relationship
between candidate biomarkers with clinical outcome. This
work serves as a practical implementation of some of those
ideas.
Appendix: Proposed algorithm for estimating pFDR and
FDR
Fit model/Eq. 1 for each gene g, g =1,⋯, G.
Calculate a p-value using ̂1g=cSE ̂1g 	 , g =1,⋯, G.
Let p1,⋯, pG denote the Gp-values. Estimate π0, the
proportion of differentially expressed genes and FP(x), the
cdf of the p-values by
̂0 ¼ W ð Þ1 ð Þm
and
F̂P xð Þ ¼ min R ð Þ; 1f gG ;
where R(γ) = #{pI ≤ γ} and W(γ) = #{pI > λ}.
For any rejection region of interest [0,γ], estimate pFDR
as
p dFDR ð Þ ¼ ̂0
F̂P ð Þ 1 1 ð Þmf g
:
Estimate FDR as
dFDR Rð Þ ¼ ̂0
F̂P ð Þ
Note: For details on choosing γ, see Section 9 of Storey
(2002).
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